Company news

CSL Limited news in 2026

CSL Limited's news releases, calls and decks from 2026, newest first.

View company

Agreements with U.S. on Drug Prices and Manufacturing

August 31, 2026

Appendix 3Y - Alison Watkins AM

August 27, 2026

Appendix 3Y - Costa Saroukos

August 27, 2026

Appendix 3Y - Cameron Price

August 27, 2026

Appendix 3Y - Samantha Lewis

August 27, 2026

Appendix 3Y - Carolyn Hewson AO

August 27, 2026

Appendix 3Y - Andrew Cuthbertson AO

August 27, 2026

Appendix 3Y - Brian McNamee AO

August 27, 2026

Notification regarding unquoted securities - CSL

August 27, 2026

World’s-First Battery-Powered Self-Unloading Bulk Carrier Now Operating in South Australia

August 26, 2026

Notification of buy-back - CSL

August 26, 2026

CSL Results Presentation for FY2026

August 17, 2026

CSL FY2026 Results

August 17, 2026

CSL Statutory Accounts for FY2026

August 17, 2026

CSL Appendix 4G and Corporate Governance Statement

August 17, 2026

Dividend/Distribution - CSL

August 17, 2026

European Commission (EC) adopts decision to revoke marketing authorisation for TAVNEOS® (avacopan) in the European Union and European Economic Area countries

August 6, 2026

Notification of cessation of securities - CSL

August 5, 2026

Notice of Investor/Analyst Briefing 2026 Full Year Result

August 4, 2026

CSL Update on Enhanced Plasma Manufacturing

July 28, 2026

CSL Marks the Completion of the First Vessel in World-Leading Transhipment Fleet for Simandou Project

July 28, 2026

CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)

July 27, 2026

CSL Delivers World's First Battery-Powered Self-Unloading Bulk Carrier to Support Adbri Operations

June 12, 2026

CSL Delivers World’s First Battery-Powered Self-Unloading Bulk Carrier to Support Adbri Operations

June 12, 2026

CSL Takes Delivery of MV CSL Kuleana, Advancing CSL International Pool Newbuild Program

June 3, 2026

CSL Canada Announces First Canadian Patient Receives HEMGENIX® (etranacogene dezaparvovec) Hemophilia B Gene Therapy in Ontario, Canada

May 20, 2026

Vaccine Adjuvant Market Set to Boom Rapidly, Witnessing Strong Growth Through 2033 | CSL Limited, Seppic

May 14, 2026

CSL: Published Large U.S. Study Finds Comparable Effectiveness Between Adjuvanted and High-Dose Influenza Vaccines in Adults 65 Years and Older

May 13, 2026

CSL: Seqirus Signs Long-Term Agreement with the Pan American Health Organization (PAHO) to Advance Pandemic Influenza Preparedness in Latin America and the Caribbean

May 12, 2026

Interim CEO 90 Day Review and Financial Update

May 10, 2026

CSL Seqirus Signs Long-Term Agreement with The Pan American Health Organization to Advance Regional Influenza Protection in the Region of the Americas

March 11, 2026

CSL: Seqirus Signs Long-Term Agreement with The Pan American Health Organization (PAHO) to Advance Regional Influenza Protection in the Region of the Americas

March 10, 2026

CSL announces expansion of Illinois plasma therapy manufacturing facility

March 9, 2026

Canada and CSL Seqirus, a Global Leader in Influenza Vaccines, agree on new Pandemic Preparedness Contract

March 6, 2026

Canada and CSL Seqirus, a Global Leader in Influenza Vaccines, agree on new Pandemic Preparedness Contract

March 5, 2026

Neffy, adrenaline nasal spray, now approved to treat anaphylaxis in Australia

February 16, 2026

CSL Half Year Results Investor Presentation

February 10, 2026

CSL Statutory Accounts for the Half Year Ended 31 December

February 10, 2026

CSL Half Year Results Announcement

February 10, 2026

Paul McKenzie retires, Gordon Naylor appointed interim CEO

February 10, 2026

← Newer news releases

Calls in 2026

Decks in 2026